期刊文献+

国内应用含左氧氟沙星方案治疗耐多药结核的系统评价 被引量:1

下载PDF
导出
摘要 目的:系统评价国内应用含左氧氟沙星方案治疗耐多药结核的有效性与安全性。方法:全面收集国内含左氧氟沙星方案为干预措施治疗耐多药结核的临床试验,利用RevM an软件进行固定效应模型的M eta分析,对不同合并结果进行了敏感度分析,用漏斗图分析发表性偏倚。结果:共11篇文章进入研究,评分指标总体优于对照组,不良反应与对照组比较并无显著降低,漏斗图提示存在发表性偏倚。结论:临床应用左氧氟沙星治疗耐多药结核效果明显,对其安全性还有待增大样本量作进一步的研究。
机构地区 天津市海河医院
出处 《天津药学》 2008年第3期77-78,共2页 Tianjin Pharmacy
  • 相关文献

参考文献10

  • 1陆宇,段连山.治疗耐药结核病的药物选择和药物研究进展[J].四川生理科学杂志,2005,27(4):172-175. 被引量:15
  • 2结核病诊断细菌学检验规程[J].中国防痨杂志,1996,18(1):28-31. 被引量:799
  • 3中华医学会结核病科学会.肺结核化学疗法[J].中华结核和呼吸系疾病杂志,1982,6:381-385.
  • 4Moher D , Cook D J , Eastwood S,et al. improving the quality of reports of Meta - analyses of randomized controlled trials : the QUOROM statement. Lancet,1999,354 (9193) :1896
  • 5Jadad AR, Moore A, carroll D, et al. Assessing the quality of reports of randomized clinical trails: Is blinding necessary? Control Clin Trials, 1996,17(1) :1
  • 6刘关键,吴泰相,康德英.Meta-分析中的统计学过程[J].中国临床康复,2003,7(4):538-539. 被引量:112
  • 7Vickers A, Goyal N, Harland R,et al. Do certain countries produce only positive results? A systematic review of controlled trials. Control Clin Trials, 1998,19 (2) : 159
  • 8Goble M , Iseman M D ,Madsen L A ,et al. Treatment of 171 patients with pulmonary tuberculosis resistant to isoniazid and rifampin. N Engl J Med , 1993 ,328:527
  • 9Rastogi N,Goh KS, Bryskier A,et al. In vitro activities of levofloxacin usedalone and in combination with first and second line antituberculous drugs against mycobacterium tuberculosis. Antimicrob Agents Chemother,1996,40:1616
  • 10陆宇,朱莉贞,段连山,严碧涯,马丽萍,梁桂芳,赵伟杰,李惠文.左氧氟沙星的抗结核作用研究[J].中华结核和呼吸杂志,2000,23(1):50-54. 被引量:146

二级参考文献20

  • 1李可欣,孙春华,曹国颖,缪竞智,傅得兴,杨湘霞.健康志愿者口服左氟沙星的体内药物动力学研究[J].中国抗生素杂志,1996,21(4):277-280. 被引量:15
  • 2段连山,梁桂芳,李惠文,于惠英,赵伟杰,郭振永.国产氧氟沙星抗结核活性的实验研究[J].中华结核和呼吸杂志,1997,20(2):98-100. 被引量:12
  • 3[1]Zhang Y,Telenti A.Genetics of drug resistance in Mycobacterium tuberculosis In:Molecular Genetics of Mycobacteria.Edited by Hatful GF,Jacobs WR Jr.ASM Press,2000:235-254.
  • 4[2]Jin D J,Gross C A.Mapping and sequencing of mutations in the Escherichla coli.RpoB gene that lead to rifampicin tesistance.J Mol Biol,1988;202:45-48.
  • 5[3]Miller L P,Crawford J T,Shinnick T M.The rpoB gene of Mycobacterium tuberculosis.Antimicrob Agents Chemother,1994 ;38:805-811.
  • 6[4]Scorpio A,Zhang Y.Mutations in pncA,a gene encoding pyrazinamidase/nicotinamidase,cause resistance to the antituberculous drug pyrazinamide in tubercle bacillus.Nature Med,1996 ;2:662-667.
  • 7[5]Rattan A,Kalia A,Ahmad N.Multidrug-resistant Mycobacterium tuberculosis:molecular perspectives.Emerg Infect Dis,1998 ;4:195-209.
  • 8[6]Cole ST,Brosch R,Parkhill J,et al.Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence.Nature,1998; 393:537-544.
  • 9[7]Heifets L B,Lindholnr Levy P F,Iseman M D.Rifambutin:minimal inhibitory and bactericidal concentrations for mycobacterium tuberculosis.Am Respir Crit Care Med,1995; 151:942-945.
  • 10[9]Mor N,Vanderkolk J,Heifets L.Inhibitory and bactericidal activities of levofloxacin against mycobacterium tuberculosis in vitro and in human macrophage.Antimicrob Agents Chemother,1994 ;38:1161-1164.

共引文献1184

同被引文献14

引证文献1

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部